GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albert Labs International Corp (XCNQ:ABRT) » Definitions » Treasury Stock

Albert Labs International (XCNQ:ABRT) Treasury Stock : C$0.00 Mil (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Albert Labs International Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Albert Labs International's treasury stock for the quarter that ended in Sep. 2023 was C$0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.


Albert Labs International Treasury Stock Historical Data

The historical data trend for Albert Labs International's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albert Labs International Treasury Stock Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
Treasury Stock
- -

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Albert Labs International Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.


Albert Labs International (XCNQ:ABRT) Business Description

Traded in Other Exchanges
N/A
Address
6996, Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of clinical pathway.

Albert Labs International (XCNQ:ABRT) Headlines

No Headlines